9/30/2013

Researchers at Karolinska Institutet in Europe will use GE Healthcare's sequencing technology to detect alleles and mutations linked to metastatic breast cancer. The deal, whose terms were not disclosed, is part of GE's initiative to invest in the development of novel molecular imaging and cancer diagnostic capabilities. The company is also investing in biopharmaceutical manufacturing.

Related Summaries